Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: Long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration

Journal of Autoimmunity

Volumn 21, Issue 3, 2003, Pages 283-293

  Nussenblatt, Robert B ^a   Thompson, Darby J S ^b   Li, Zhuqing ^a   Peterson, Jan S ^b   Robinson, Randy R ^c   Shames, Richard S ^c   Nagarajan, Sudha ^c   Tang, Meina Tao ^c   Mailman, Michelle ^c   Velez, Gisela ^a   Roy, Chandra ^a   Levy Clarke, Grace A ^a   Suhler, Eric B ^a   Djalilian, Ali ^a   Sen, Hatice Nida ^a   Al Khatib, Shadi ^a   Ursea, Roxana ^a   Srivastava, Sunil ^a   Bamji, Allison ^a   Mellow, Susan ^a   Sran, Pushpa ^a   Waldmann, Thomas A ^d   Buggage, Ronald R ^a   more..

^a NATIONAL EYE INSTITUTE   (United States)

^b EMMES CORPORATION   (United States)

^c PROTEIN DESIGN LABS INC   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Autoimmunity; Daclizumab; IL 2 receptor; Immunosuppression; Inflammation; Uveitis

Indexed keywords

DACLIZUMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; PROTEIN SUBUNIT; RECOMBINANT INTERLEUKIN 2;

ADULT; ARM; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INFUSION; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INJECTION; INJURY; LIVER DISEASE; LONG TERM CARE; MALE; MUSCULOSKELETAL DISEASE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SIDE EFFECT; SKIN DISEASE; TREATMENT OUTCOME; UVEITIS;

EID: 10744222484     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-8411(03)00113-6     Document Type: Conference Paper

References (13)

1. Queen C., Schneider W.P., Selick H.E., Payne P.W., Landolfi N.F., Duncan J.F., et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A. 86:1989;10029-10033.
2. Vincenti F., Kirkman R., Light S., Bumgardner G., Pescovitz M., Halloran P., et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med. 338:1998;161-165.
3. Reed M.H., Shapiro M.E., Strom T.B., Milford E.L., Carpenter C.B., Weinberg D.S., et al. Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody. Transplantation. 47:1989;55-59.
4. Jabs D.A., Rosenbaum J.T., Foster C.S., Holland G.N., Jaffe G.J., Louie J.S., et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 130:2000;492-513.
5. Caspi R.R. Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis. Int Rev Immunol. 21:2002;197-208.
6. Guex-Crosier Y., Raber J., Chan C.C., Kriete M.S., Benichou J., Pilson R.S., et al. Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J Immunol. 158:1997;452-458.
7. Nussenblatt R.B., Fortin E., Schiffman R., Rizzo L., Smith J., Van Veldhuisen P., et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A. 96:1999;7462-7466.
8. Hogan M.J., Kimura S.J., Thygeson P. Signs and symptoms of uveitis, I: anterior uveitis. Am J Ophthalmol. 47:1959;155-170.
9. Nussenblatt R.B., Palestine A.G., Chan C.C., Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 92:1985;467-471.
10. Fayer B.E., Soni P.P., Binger M.H., Mould D.R., Satoh H. Determination of humanized anti-Tac in human serum by a sandwich enzyme linked immunosorbent assay. J Immunol Methods. 186:1995;47-54.
11. Krueger J.G., Walters I.B., Miyazawa M., Gilleaudeau P., Hakimi J., Light S., et al. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol. 43:2000;448-458.
12. Junghans R.P., Waldmann T.A. Metabolism of Tac (IL2Rα): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding. J Exp Med. 183:1996;1587-1602.
13. Van Parijs L., Biuckians A., Ibragimov A., Alt F.W., Willerford D.M., Abbas A.K. Functional responses and apoptosis of CD25 (IL-2R alpha)-deficient T cells expressing a transgenic antigen receptor. J Immunol. 158:1997;3738-3745.